FindTrial
Sign In

The prevalence of the IGSF-1 mutation in children who develop central hypothyroidism after starting Growth Hormone treatment.

The prevalence of the IGSF-1 mutation in children who develop central hypothyroidism after starting Growth Hormone treatment. - The prevalence of the IGSF-1 mutation

Status
Unknown
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON38491
Enrollment
27
Registered
2013-04-23
Start date
Unknown
Completion date
Unknown
Last updated
2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hypothyroidism too little thyroid hormones

Interventions

None listed

Sponsors

Academisch Medisch Centrum
Lead Sponsor

Eligibility

Age
2 Years to 17 Years

Inclusion criteria

Inclusion criteria: Children receiving thyroxine within two years after starting growth hormone treatment.

Exclusion criteria

Exclusion criteria: Children with isolated Growth Hormone deficiency ( not using thyroxine ) or children already known with Multiple Pituitary Hormone deficiency at the moment of starting growth hormone treatment.

Design outcomes

Primary

MeasureTime frame
- To gather the exact medical data of the 27 children who are being treated with thyroxine, to confirm that they were diagnosed with central hypothyroidism. (based on the concentrations of FT4 and TSH before starting with GH) - To evaluate growth velocity and compare this with children diagnosed with isolated growth hormone deficiency. - To determine the prevalence of the occurrence of the IGSF-1 mutation in children which develop a central hypothyroidism after start of GH.—

Secondary

MeasureTime frame
N.V.T.—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)